no help available
no help available
userThe blue social bookmark and publication sharing system.
actions for all displayed bookmarks:
export:
sort:
- criterion: date, title
- order: ascending, descending
others:
- display: all, bookmarks only
- bookmarks per page: 5 10 20 50 100
bookmarks
actions for all displayed publications:
export:
sort:
- criterion: date, title
- order: ascending, descending
- advanced...
others:
- display: all, publications only
- publications per page: 5 10 20 50 100
publications (68)
- related tags
- concepts
- tags
- Humans
- Research
- Growth
- Endothelial
- Factor
- Vascular
- protein
- blood
- Neoplasms
- metabolism
- methods
- Animals
- cells
- Human
- therapy
- pathology
- &
- A
- drug
- Tyrosine
- Cell
- analysis
- Cells
- Proteins
- Factors
- response
- Biological
- genetics
- Neovascularization
- Antibodies
- physiology
- Tumor
- Female
- Kinase
- Pathologic
- effects
- pharmacology
- Kinases
- Laboratories
- use
- Inhibitors
- Receptors
- Blood
- therapeutic
- Male
- Receptor
- inhibitors
- Protein-Tyrosine
- Chemistry
- antagonists
- No matching items.
- M. Kelley, and B. DeSilva. AAPS.J. 9(2):E156-E163 (2007)M. Kelley, and B. DeSilva. AAPS.J. 9(2):E156-E163 (2007)3 years and 4 months agoby kanefendt1
- W. Nowatzke, and E. Woolf. AAPS.J. 9(2):E117-E122 (2007)W. Nowatzke, and E. Woolf. AAPS.J. 9(2):E117-E122 (2007)3 years and 4 months agoby kanefendt1
- P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. R. Tonra, L. Witte, and K. Alitalo. Cancer Res. 67(2):593-599 (2007)P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. R. Tonra, L. Witte, and K. Alitalo. Cancer Res. 67(2):593-599 (2007)3 years and 4 months agoby kanefendt1
- &
- Animals
- Antibodies
- Antitumor
- Assays
- BALB
- Binding
- C
- Cell
- D
- Endothelial
- Factor
- Growth
- Human
- Humans
- Immunohistochemistry
- Inbred
- Ligands
- Mice
- Model
- Monoclonal
- Neoplasms
- Neovascularization
- Nude
- Pathologic
- Processes
- Receptor-3
- Research
- Vascular
- Xenograft
- analysis
- antagonists
- blood
- immunology
- inhibitors
- metabolism
- pharmacology
- supply
- therapy
& Animals Antibodies Antitumor Assays BALB Binding C Cell D Endothelial Factor Growth Human Humans Immunohistochemistry Inbred Ligands Mice Model Monoclonal Neoplasms Neovascularization Nude Pathologic Processes Receptor-3 Research Vascular Xenograft analysis antagonists blood immunology inhibitors metabolism pharmacology supply therapy - T. Makinen, C. Norrmen, and T. V. Petrova. Cell Mol.Life Sci. 64(15):1915-1929 (2007)T. Makinen, C. Norrmen, and T. V. Petrova. Cell Mol.Life Sci. 64(15):1915-1929 (2007)3 years and 4 months agoby kanefendt1
- A. P. Dei Tos. Int.J.Biol.Markers 22(1 Suppl 4):S3-S9 (2007)A. P. Dei Tos. Int.J.Biol.Markers 22(1 Suppl 4):S3-S9 (2007)3 years and 4 months agoby kanefendt1
- F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro. Int.J.Biol.Markers 22(1 Suppl 4):S10-S23 (2007)F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro. Int.J.Biol.Markers 22(1 Suppl 4):S10-S23 (2007)3 years and 4 months agoby kanefendt2
- &
- Antibodies
- Biological
- Carcinoma
- Dosage
- Drug
- Epidermal
- Factor
- Gene
- Growth
- Human
- Humans
- Immunohistochemistry
- Inhibitors
- Kinase
- Kinases
- Lung
- Markers
- Monoclonal
- Mutation
- Neoplasm
- Neoplasms
- Non-Small-Cell
- Phosphoproteins
- Predictive
- Protein
- Protein-Tyrosine
- Proteins
- Proto-Oncogene
- Quinazolines
- Receptor
- Resistance
- Tests
- Tyrosine
- Value
- analysis
- antagonists
- c-akt
- drug
- effects
- erbB-2
- erbB-3
- genetics
- identify
- inhibitors
- of
- protein
- response
- therapeutic
- therapy
- use
& Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use - Samuel Deprimo, Carlo Bello, John Smeraglia, Charles Baum, Dominic Spinella, Brian Rini, M. Dror Michaelson, and Robert Motzer. Journal of Translational Medicine 5(1):32 (2007)Samuel Deprimo, Carlo Bello, John Smeraglia, Charles Baum, Dominic Spinella, Brian Rini, M. Dror Michaelson, and Robert Motzer. Journal of Translational Medicine 5(1):32 (2007)3 years and 4 months agoby kanefendt1
- J. W. Findlay, and R. F. Dillard. AAPS.J. 9(2):E260-E267 (2007)J. W. Findlay, and R. F. Dillard. AAPS.J. 9(2):E260-E267 (2007)3 years and 4 months agoby kanefendt1
- S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P. M. Schlag, W. Kemmner, and M. Hocker. J.Clin.Oncol. 24(2):228-240 (2006)S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P. M. Schlag, W. Kemmner, and M. Hocker. J.Clin.Oncol. 24(2):228-240 (2006)3 years and 4 months agoby kanefendt1
- 80
- Adenocarcinoma
- Adult
- Aged
- Antibodies
- C
- Cell
- Chemistry
- D
- Disease-Free
- Endothelial
- Factor
- Growth
- Humans
- Immunohistochemistry
- Laboratories
- Line
- Lymphatic
- Messenger
- Metastasis
- Middle
- Neoplasms
- Prognosis
- RNA
- Receptor-3
- Research
- Stomach
- Survival
- Tumor
- Vascular
- analysis
- and
- blood
- genetics
- identify
- methods
- mortality
- over
- supply
80 Adenocarcinoma Adult Aged Antibodies C Cell Chemistry D Disease-Free Endothelial Factor Growth Humans Immunohistochemistry Laboratories Line Lymphatic Messenger Metastasis Middle Neoplasms Prognosis RNA Receptor-3 Research Stomach Survival Tumor Vascular analysis and blood genetics identify methods mortality over supply - J. W. Lee, V. Devanarayan, Y. C. Barrett, R. Weiner, J. Allinson, S. Fountain, S. Keller, I. Weinryb, M. Green, L. Duan, J. A. Rogers, R. Millham, P. J. O'Brien, J. Sailstad, M. Khan, C. Ray, and J. A. Wagner. Pharm.Res. 23(2):312-328 (2006)J. W. Lee, V. Devanarayan, Y. C. Barrett, R. Weiner, J. Allinson, S. Fountain, S. Keller, I. Weinryb, M. Green, L. Duan, J. A. Rogers, R. Millham, P. J. O'Brien, J. Sailstad, M. Khan, C. Ray, and J. A. Wagner. Pharm.Res. 23(2):312-328 (2006)3 years and 4 months agoby kanefendt1
- A. Woywodt, A. D. Blann, T. Kirsch, U. Erdbruegger, N. Banzet, M. Haubitz, and F. gnat George. J.Thromb.Haemost. 4(3):671-677 (2006)A. Woywodt, A. D. Blann, T. Kirsch, U. Erdbruegger, N. Banzet, M. Haubitz, and F. gnat George. J.Thromb.Haemost. 4(3):671-677 (2006)3 years and 4 months agoby kanefendt1
- S. E. Deprimo, C. Friece, X. Huang, J. Smeraglia, L. Sherman, M. Collier, C. Baum, A. D. Elias, H. J. Burstein, and K. D. Miller. J Clin Oncol Meeting Abstracts 24(18_suppl):578 (2006)S. E. Deprimo, C. Friece, X. Huang, J. Smeraglia, L. Sherman, M. Collier, C. Baum, A. D. Elias, H. J. Burstein, and K. D. Miller. J Clin Oncol Meeting Abstracts 24(18_suppl):578 (2006)3 years and 4 months agoby kanefendt1
- P. Chomczynski, and N. Sacchi. Nat.Protoc. 1(2):581-585 (2006)P. Chomczynski, and N. Sacchi. Nat.Protoc. 1(2):581-585 (2006)3 years and 4 months agoby kanefendt1
- C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg. Clin.Cancer Res. 14(19):5967-5976 (2008)C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg. Clin.Cancer Res. 14(19):5967-5976 (2008)3 years and 4 months agoby kanefendt1
- J. Cummings, T. H. Ward, A. Greystoke, M. Ranson, and C. Dive. Br.J.Pharmacol. 153(4):646-656 (2008)J. Cummings, T. H. Ward, A. Greystoke, M. Ranson, and C. Dive. Br.J.Pharmacol. 153(4):646-656 (2008)3 years and 4 months agoby kanefendt1
- &
- Adherence
- Agents
- Animals
- Antineoplastic
- Assay
- Biomarkers
- Cell
- Clinical
- Control
- Death
- Drug
- Enzyme-Linked
- Europe
- Evaluation
- Guideline
- Guidelines
- Humans
- Immunosorbent
- Keratin-18
- Laboratories
- Mass
- Pharmacological
- Preclinical
- Proteins
- Quality
- Reproducibility
- Research
- Results
- Spectrometry
- Terminology
- Topic
- Trials
- analysis
- as
- drug
- effects
- jurisprudence
- legislation
- methods
- of
- pharmacology
- protein
- standards
- therapeutic
- use
& Adherence Agents Animals Antineoplastic Assay Biomarkers Cell Clinical Control Death Drug Enzyme-Linked Europe Evaluation Guideline Guidelines Humans Immunosorbent Keratin-18 Laboratories Mass Pharmacological Preclinical Proteins Quality Reproducibility Research Results Spectrometry Terminology Topic Trials analysis as drug effects jurisprudence legislation methods of pharmacology protein standards therapeutic use - H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller. J Clin Oncol 26(11):1810-1816 (2008)H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller. J Clin Oncol 26(11):1810-1816 (2008)3 years and 4 months agoby kanefendt1
- &
- Administration
- Adult
- Aged
- Agents
- Anthracyclines
- Antineoplastic
- Biological
- Breast
- Bridged
- Carcinoma
- Chemotherapy
- Combined
- Compounds
- Diseases
- Drug
- Fatigue
- Female
- Gastrointestinal
- Growth
- Hematologic
- Humans
- Indoles
- Inflammation
- Kinase
- Kinases
- Markers
- Middle
- Neoplasms
- Oral
- Plasma
- Protein-Tyrosine
- Protocols
- Pyrroles
- Rate
- Schedule
- Survival
- Taxoids
- Tumor
- Tyrosine
- administration
- adverse
- analysis
- antagonists
- blood
- chemically
- classification
- dosage
- drug
- effects
- induced
- inhibitors
- methods
- mortality
- response
- secondary
- therapeutic
- therapy
- use
& Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use - F. Cappuzzo. Lung Cancer 60(2):160-165 (2008)F. Cappuzzo. Lung Cancer 60(2):160-165 (2008)3 years and 4 months agoby kanefendt1
- &
- Analysis
- Carcinoma
- Clinical
- DNA
- Drug
- Epidermal
- Factor
- Fluorescence
- Growth
- Humans
- Hybridization
- In
- Inhibitors
- Kinase
- Lung
- Mutation
- Mutational
- Neoplasm
- Neoplasms
- Non-Small-Cell
- Patient
- Population
- Protein
- Receptor
- Resistance
- Selection
- Situ
- Topic
- Trials
- Tyrosine
- analysis
- antagonists
- as
- drug
- genetics
- identify
- inhibitors
- protein
- response
- therapeutic
- therapy
- use
& Analysis Carcinoma Clinical DNA Drug Epidermal Factor Fluorescence Growth Humans Hybridization In Inhibitors Kinase Lung Mutation Mutational Neoplasm Neoplasms Non-Small-Cell Patient Population Protein Receptor Resistance Selection Situ Topic Trials Tyrosine analysis antagonists as drug genetics identify inhibitors protein response therapeutic therapy use - V. Brower. J.Natl.Cancer Inst. 101(12):846-847 (2009)V. Brower. J.Natl.Cancer Inst. 101(12):846-847 (2009)3 years and 4 months agoby kanefendt1
- A
- Analysis
- Angiogenesis
- Animals
- Antibodies
- Benzenesulfonates
- Biological
- Cells
- Cytokines
- Disease-Free
- Endothelial
- Factor
- Growth
- Humans
- Indoles
- Inhibitors
- Markers
- Monoclonal
- Neoplasms
- Pyridines
- Pyrroles
- Survival
- Tumor
- Vascular
- blood
- drug
- effects
- metabolism
- mortality
- pathology
- pharmacology
- response
- supply
- therapeutic
- therapy
- use
A Analysis Angiogenesis Animals Antibodies Benzenesulfonates Biological Cells Cytokines Disease-Free Endothelial Factor Growth Humans Indoles Inhibitors Markers Monoclonal Neoplasms Pyridines Pyrroles Survival Tumor Vascular blood drug effects metabolism mortality pathology pharmacology response supply therapeutic therapy use